Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
15 Aprile 2024 - 1:00PM
Business Wire
A pivotal Phase III trial for advanced liver
cancer, approved by FDA & EMA and a MASH Phase IIb are
enrolling patients
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncological and inflammatory diseases,
today announced that Biomedicines published an article titled
“Namodenoson at the Crossroad of Metabolic Dysfunction-Associated
Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC)”.
Biomedicines is a highly reputable journal that publishes articles
on clinical and basic science topics in medicine.
https://www.mdpi.com/2227-9059/12/4/848.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240415044511/en/
Namodenoson mechanism of action (Graphic:
Business Wire)
The article’s first author, Dr. Ohad Etzion, is a renowned key
opinion leader (KOL) in the Hepatology field and is the engine for
some of the novel drugs under development for the treatment of MASH
and additional liver diseases. Dr. Etzion is the Head, Department
of Gastroenterology and Liver Diseases, at Soroka University
Medical Center, Beer Sheva, Israel.
The Biomedicines article presents the pre-clinical and clinical
activity of Namodenoson and the mechanism of action through which
the drug induces the anti-cancer activity and at the same time the
liver protective effects. This dual activity enables the drug to
have positive effects in both liver cancer and MASH.
Currently, Namodenoson is being evaluated in LiverationTM, a
pivotal Phase III study for advanced liver cancer that has been
approved by both the U.S. Food and Drug Administration (FDA) and
the European Medicines Agency (EMA), and also in a Phase IIb study
in patients with MASH.
“We are very much encouraged by the clinical data from the Phase
II study in HCC and the Phase IIa study in MASH. The drug mechanism
of action which is presented in the manuscript and entails
inflammatory cytokine inhibition together with the stimulation of
positive cytokines, position Namodenoson as a promising safe drug,”
stated Dr. Etzion.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with
high affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson was evaluated in Phase II trials for two indications,
as a second line treatment for hepatocellular carcinoma, and as a
treatment for non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in
diseased cells whereas low expression is found in normal cells.
This differential effect accounts for the excellent safety profile
of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's lead drug candidate, Piclidenoson recently reported
topline results in a Phase III trial for psoriasis and is expected
to commence a pivotal Phase III. Can-Fite's cancer and liver drug,
Namodenoson, is being evaluated in a Phase IIb trial for the
treatment metabolic dysfunction-associated steatohepatitis (MASH),
a Phase III pivotal trial for hepatocellular carcinoma (HCC), and
the Company is planning a Phase IIa study in pancreatic cancer.
Namodenoson has been granted Orphan Drug Designation in the U.S.
and Europe and Fast Track Designation as a second line treatment
for HCC by the U.S. Food and Drug Administration. Namodenoson has
also shown proof of concept to potentially treat other cancers
including colon, prostate, and melanoma. CF602, the Company's third
drug candidate, has shown efficacy in the treatment of erectile
dysfunction. These drugs have an excellent safety profile with
experience in over 1,600 patients in clinical studies to date. For
more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. All
statements in this communication, other than those relating to
historical facts, are “forward looking statements”. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to any resurgence of the COVID-19 pandemic and the war
between Israel and Hamas; risks related to not satisfying the
continued listing requirements of NYSE American; and statements as
to the impact of the political and security situation in Israel on
our business. More information on these risks, uncertainties and
other factors is included from time to time in the “Risk Factors”
section of Can-Fite’s Annual Report on Form 20-F filed with the SEC
on March 28, 2024 and other public reports filed with the SEC and
in its periodic filings with the TASE. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Can-Fite undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240415044511/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Grafico Azioni Can Fite BioPharma (AMEX:CANF)
Storico
Da Ott 2024 a Dic 2024
Grafico Azioni Can Fite BioPharma (AMEX:CANF)
Storico
Da Dic 2023 a Dic 2024
